Novel EP4 Receptor Agonist‐Bisphosphonate Conjugate Drug (C1) Promotes Bone Formation and Improves Vertebral Mechanical Properties in the Ovariectomized Rat Model of Postmenopausal Bone Loss

ABSTRACT Current treatments for postmenopausal osteoporosis aim to either promote bone formation or inhibit bone resorption. The C1 conjugate drug represents a new treatment approach by chemically linking the antiresorptive compound alendronate (ALN) with the anabolic agent prostanoid EP4 receptor a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of bone and mineral research 2015-04, Vol.30 (4), p.670-680
Hauptverfasser:	Liu, Careesa C, Hu, Sally, Chen, Gang, Georgiou, John, Arns, Steve, Kumar, Nag S, Young, Robert N, Grynpas, Marc D
Format:	Artikel
Sprache:	eng
Schlagworte:	ANABOLICS Animals ANTIRESORPTIVES Body Weight - drug effects Bone Development - drug effects BONE HISTOMORPHOMETRY Bone Remodeling Diphosphonates - pharmacology Diphosphonates - therapeutic use Disease Models, Animal Female Humans OSTEOPOROSIS Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - physiopathology Ovariectomy PRECLINICAL STUDIES Rats Rats, Sprague-Dawley Receptors, Prostaglandin E, EP4 Subtype - agonists Spine - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!